Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial

Conclusion: In sum, single-agent pembrolizumab was well tolerated as salvage therapy in a small cohort of patients with unresectable, locally advanced or metastatic penile SCC. Pembrolizumab produced an objective response in an MSI-H tumor, yet it did not control disease in two patients with MSS penile SCC. Rationale combination therapies, including pembrolizumab, warrant further investigation.Trial registration: ClinicalTrials.gov identifier:NCT02721732. Registered March 23, 2016.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research